confirming the ADC science has become more mature. Technological advancements such as linker technology and more effective payloads which are likely to increase the effectiveness of ADCs are ...

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as ...

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology ...

Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline ...

While ADC development is accelerating rapidly, researchers need more sophisticated tools to evaluate ADC efficacy and tumor penetration in models that better reflect the complex tumor microenvironment ...